Tag: DMX-652
Dimerix’s DMX-652 acquisition to bolster kidney disease therapy development
Dimerix recently announced the acquisition of DMX-652 from Mission Therapeutics, adding a Phase II-ready acute kidney injury (AKI) program with a differentiated mechanism. The...